Provided by Tiger Fintech (Singapore) Pte. Ltd.

Biohaven Pharmaceutical Holding Co Ltd.

19.71
-2.9100-12.86%
Volume:1.53M
Turnover:31.51M
Market Cap:2.01B
PE:-2.12
High:22.22
Open:22.00
Low:19.70
Close:22.62
Loading ...

Biohaven Presents New Data with BHV-7000 Once-Daily Extended-Release Formulation Demonstrating Excellent Safety Profile and Nonclinical Data Updates at American Epilepsy Society 2024 Annual Meeting

PR Newswire
·
06 Dec 2024

Analysts Offer Insights on Healthcare Companies: Biohaven Ltd. (BHVN), Arrowhead Pharmaceuticals (ARWR) and Heron Therapeutics (HRTX)

TIPRANKS
·
06 Dec 2024

Biohaven Price Target Raised to $61.00/Share From $58.00 by RBC Capital

Dow Jones
·
05 Dec 2024

RBC Raises Price Target on Biohaven to $61 From $58, Keeps Outperform, Speculative Risk

MT Newswires Live
·
04 Dec 2024

Biohaven Ltd : RBC Raises Target Price to $61 From $58

THOMSON REUTERS
·
04 Dec 2024

Jefferies Sticks to Their Buy Rating for Biohaven Ltd. (BHVN)

TIPRANKS
·
26 Nov 2024

Analysts Offer Insights on Healthcare Companies: Alnylam Pharma (ALNY), Vigil Neuroscience Inc (VIGL) and Biohaven Ltd. (BHVN)

TIPRANKS
·
26 Nov 2024

Biohaven Price Target Maintained With a $59.00/Share by HC Wainwright & Co.

Dow Jones
·
26 Nov 2024

Biohaven Is Maintained at Outperform by RBC Capital

Dow Jones
·
26 Nov 2024

Biohaven study had positive signal for obesity, says H.C. Wainwright

TIPRANKS
·
26 Nov 2024

Scholar Rock Stock Jumps As Rival Biohaven's Muscle-Wasting Drug Flunks Pivotal Study

Benzinga
·
26 Nov 2024

Biohaven outcome ‘fundamental net positive’ for Scholar Rock, says JPMorgan

TIPRANKS
·
26 Nov 2024

Biohaven Ltd : RBC Cuts Target Price to $58 From $66

THOMSON REUTERS
·
25 Nov 2024

RBC Cuts Price Target on Biohaven to $58 From $66, Maintains Outperform Rating

MT Newswires Live
·
25 Nov 2024

Biohaven falls -9.0%

TIPRANKS
·
25 Nov 2024

Biohaven Shares Dip 0.8% as Spinal Muscular Atrophy Drug Fails to Meet Study Goal

THOMSON REUTERS
·
25 Nov 2024

Scholar Rock Holding Shares Jump 37.5% After Rival Biohaven's Rare Genetic Disorder Drug Fails Trial Goal

THOMSON REUTERS
·
25 Nov 2024

Sector Update: Health Care Stocks Edge Higher Premarket Monday

MT Newswires Live
·
25 Nov 2024

BUZZ-Biohaven falls as genetic disorder drug fails to meet goal in late-stage study

Reuters
·
25 Nov 2024

Biohaven Says Potential Neurodegenerative Disease Treatment Failed to Achieve Statistical Significance; Shares Fall Pre-Bell

MT Newswires Live
·
25 Nov 2024